Presentation of results for second quarter 2013
DiaGenic will present results for second quarter 2013 on Friday 23 August 2013. Interim report and presentation slides will be posted on www.newsweb.no and on DiaGenic’s web page: www.diagenic.com on 23 August at approximately 08:00 CET.
A conference call for presentation of the results is scheduled the same day at 09:00 CET.
A lunch presentation will be held at 11:00 CET at DNB’ premises, Dronning Eufemias gate 30, 0191 Oslo. Participants for the lunch presentation are kindly asked to make prior notice to: firstname.lastname@example.org or contact Nina Vatlum Hasle, Corporate Access Manager, at DNB Markets.
Please use the dial-in details listed below, corresponding to your location, to participate in the conference call at 09:00 CET. The conference ID is: 8131806
Participant Access - Dial in 5-10 minutes prior to the start time using the number
|Participants, Local - Oslo, Norway:||+472350 0486|
|Participants, Local - Stockholm, Sweden:||+46(0)8 5876 9446|
|Participants, Local - Copenhagen, Denmark:||+4538 32 28 69|
|Participants, Local - New York, United States of America:||+1718 354 1158|
|Participants, Local - London, United Kingdom:||+44(0)20 3427 1919|
Please use the Direct Access link below to follow the presentation slides in conference call at 09:00 CET:
|Adobe Connect Web Meeting:|
|To be entered directly into your Adobe Connect Event click on the Direct Access Link:
Need Help? Contact Customer Support:
Phone : +353 (0) 23 88 32131
E-Mail : email@example.com
The conference call will be available in re-play after the presentation on DiaGenic’s webpage www.diagenic.com
Paul de Potocki, CEO
Telephone: 47 2324 8950
Ruben Ekbråten, CFO
Telephone: 47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com